RBC Capital downgrades BioCryst to Sector Perform

BioCryst Pharmaceuticals (BCRX) came under scrutiny after RBC Capital said the company faces a “challenging near-term outlook,” following strong late-stage data from Pharvaris (PHVS) for hereditary angioedema therapy. RBC downgraded BioCryst to “Sector Perform” from “Outperform…”